Sonata Therapeutics is revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. The company's product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through its pioneering science, Sonata identifies new targets for therapeutics that induce the release of a programmed diversity of signals that drive curative microenvironments. Founded in 2022 by Flagship Pioneering, Sonata is generating a growing pipeline of small molecule drugs and genetic therapeutics, with preclinical programs that address a broad range of oncologic indications, as well as exploratory efforts in fibrosis and autoimmune disorders. For more information, visit SonataTx.com.